US ERA ARCHIVE DOCUMENT

EPA MRID Number 458677-07

Data Requirement:

EPA DP Barcode D288775

EPA MRID 458677-07

EPA Guideline 70-1(Special Study)

Test material: Purity: 98.6%

Common name Atrazine Chemical name: IUPAC

CAS name 6-chloro-N-ethyl-N'-(1-methylethyl)-1,3,5-triazine-2,4-diamine

CAS No. 1912-24-9

Synonyms

EPA PC Code: 80803

Primary Reviewer: Thomas M. Steeger, Ph.D., Senior Biologist **Date:** April 6, 2003

Environmental Fate and Effects Division, ERB 4,

U. S. Environmental Protection Agency

Secondary Reviewer(s): Joseph E. Tietge, M.S., Research Aquatic Biologist **Date:** Mid-Continent Ecology Division, National Health and Environmental Effects Research Laboratory

(Duluth), U. S. Environmental Protection Agency

Stephanie Irene, Ph.D., Senior Advisor **Date**:

Environmental Fate and Effects Division, ERB 3, U. S. Environmental Protection Agency

Mary J. Frankenberry, Senior Statistician Date:

Environmental Fate and Effects Division, ERB 3, U. S. Environmental Protection Agency

EPA PC Code 080803

Date Evaluation Completed: 05/31/2003

<u>CITATION</u>: Goleman, W. L. and J. A. Carr. 2003. Response of larval *Xenopus laevis* to Atrazine Exposure: Assessment of Metamorphosis and Gonadal and Laryngeal Morphology. The Institute of Environmental and Human Health, Texas Tech University, Texas Tech University Health Sciences Center, Lubbock, Texas. Sponsor: Syngenta Crop Protection, Inc., Laboratory Study ID ECORISK Number TTU-01.

EXECUTIVE SUMMARY:

In a 78-day exposure, 48- to 72-hr post-hatch African clawed frog (*Xenopus laevis*) larvae were exposed to nominal concentrations of 1, 10 and 25 μg atrazine/L in FETAX medium, FETAX medium alone (negative control), 17- β estradiol, dihydrotestosterone, or solvent control (0.0025% ethanol) in a static renewal system where 50% exposure solution water changes occurred every 72 hours. For the first seven days, 60 - 65 larvae were maintained in 100 mL of exposure solution. On day 14, animals were transferred to 1 L of exposure solution, and by Day 21, animals were maintained in 4 L of exposure solution. At NF Stage 66 (forelimb emergence and complete tail resorption) animals were weighed, measured for snout-vent length and examined for gonadal gross morphology. Larynx and gonads also underwent histological analysis.

Mortality over the study period ranged from 10 to 14% for those animals that reached stage 66 by 80 days post-hatch. Time to complete metamorphosis was not significantly different across treatments although the specific time was not reported. In all treatments, weight and snout-vent length were inversely proportional to the number of days required to complete metamorphosis, *i.e.*, animals completing metamorphosis early tended to be larger than animals that took longer to complete metamorphosis. Sex ratios ranged from 48% to 50% male across all treatments except for estradiol, which skewed the ratio in favor of females (67%). While the incidence of intersex was correlated with atrazine treatment concentrations, only the 25 µg atrazine/L (4.7%) and estradiol-treated (7.4%) males had incidence rates significantly different from negative (0.6%) and solvent (0.0%) controls. Intersex in males treated with 25 µg atrazine/L contained distinguishable testicular and ovarian tissue, while males treated with estradiol sometimes contained ambiguous tissue structures.

There was no difference in the cross-sectional area of larynx dilator muscle in any atrazine-treated males relative to negative controls. Dihydrotestosterone-treated females had significantly larger cross-sectional dilator muscle areas than solvent control females.

Although the report concluded that atrazine did not impact length, weight, time to metamorphosis or dilator muscle area relative to controls, it did conclude that exposure to 25 μg atrazine/L appeared to significantly increase the number of intersex males and animals with discontinuous gonads. However, the observation that both body weight and length were inversely correlated with the length of time to complete metamorphosis suggested that animals in all treatment groups were developmentally impaired. Also, the fact that 17- β estradiol treatment only resulted in 67% females, further suggested that study animals were not entirely responsive to the positive control. Although dissolved oxygen did not appear to drop below 3.9 mg/L, ammonia levels ranged as high as 27 mg/L suggesting that the 50% static renewal and loading rates (number of tadpoles per liter of exposure solution) may have resulted in poor water quality that could, in turn, impair the development of test animals. Furthermore, roughly 42% of the animals were assumed not to have reached stage 66 by Day 78, suggesting that a large proportion of the animals were not developing at all. Because of the declining condition of the frogs with increased length of time to maturity, it is uncertain whether these animals completed metamorphosis and/or survived. Furthermore, because all the animals in the study had not undergone metamorphosis, the percent initiating metamorphosis, time to metamorphosis and percentage of gonadal abnormalities could not be accurately calculated relative to the total animals used in the study.

This study indicates that only one exposure level (25 ug/L) produced developmental effects in frogs, but because of design problems the study did not establish a dose-response relationship between atrazine exposure and developmental effects in frogs. The ability of this study to serve as a sensitive indicator of developmental effects is also in question because of the impaired condition of the animals.

I. MATERIALS AND METHODS

GUIDELINE FOLLOWED: Nonguideline Study

COMPLIANCE: Not conducted under full Good Laboratory Practices; however, most

of the practices as defined by 40 CFR Part 160, August 19, 1989, were established for this study, including but not limited to:

Written, authorized protocol

- Written, authorized Standard Operating Procedures for all key procedures.
- Organization and Personnel were sufficient in terms of number, education, training and experience.
- Facilities were of suitable size and construction
- Equipment used was of appropriate design and adequate capacity.
- Test material identity, strength, purity and composition were characterized.
- Independent QA Inspections were conducted.
- Final Report was written
- Raw data, documentation, records, protocols, and final report were archieved.

A. MATERIALS:

1. Test Material Atrazine

Description: Not reported

Lot No./Batch No.: Not reported

Purity: 98.6%

Stability of compound

under test conditions: Not reported

Storage conditions of

test chemicals: Not reported

2. Test organism:

Species: African clawed frog (*Xenopus laevis*)

Age at test initiation: 48 - 72 hr larvae

Weight at study initiation: (mean and range) Not reported Length at study initiation: (mean and range) Not reported

Source:

Six breeding pairs of *X. laevis* obtained from Xenopus Express (Homosassa, FL) artificially induced to spawn.

B. STUDY DESIGN:

Objective:

1. To determine the response of larval *Xenopus laevis* to atrazine by assessing the metamorphosis and reproductive indices when animals are exposed from 48 - 72 hours after hatching until the completion of metamorphosis. Indices to be evaluated include percent initiating metamorphosis, percent completing metamorphosis, time to metamorphosis, percentage of intersex gonads, fresh post-mortem body weight, snout-vent length, and laryngeal size.

1. Experimental Conditions

a) Range-finding Study: Trials 1 - 3 were conducted in 0.1x Holtfreter's solution and were terminated due to unexpectedly high mortality in all concentrations. In Trial 1, larvae were transferred 48 hr post-hatch and all the transferred animals died within 24 hours of transfer from "damaged abdomens". In Trials 2 and 3, exposures began when larvae were less than 24 hrs old resulting in "unacceptably high mortality" and poor growth leaving study authors to conclude that 0.1x Holtfretter's was unsuitable as a medium for raising larvae. FETAX medium was used in the fourth and final attempt at a definitive study.

b) Definitive Study

Table 1. Experimental Parameters

| Parameter | Details |
|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Acclimation: period: Conditions: (same as test or not) Feeding: Health: (any mortality observed) | breeding adults maintained separately for 7 days before breeding; maintained in 45-L glass tanks containing 18-L of ultra-pure water at $22 \pm 1^{\circ}$ C. Beginning 4 days prior to breeding, adult tank water changed to FETAX by daily 50% medium changes. |
| Duration of the test | 78 days or until frogs reached NF stage 66 (forelimb emergence and complete tail resorption) of development |
| Test condition | |
| static/flow- through | static renewal |
| Type of dilution system for flow-through method. | NA |
| Renewal rate for static renewal | 50% exposure solution change every 72 hours |

| Parameter | Details |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Aeration, if any | not reported |
| <u>Test vessel</u> | |
| Material: (glass/stainless steel) Size: Fill volume: | Glass beaker Initially 250 mL; on Day 7 transferred to 2-L beakers; on Day 21 transferred to 10-L beakers Initially 100 mL; on Day 7 filled with 1-L; on Day 21 filled with 4 L |
| Source of dilution water Quality: | tap water run through reverse osmosis and deionizer to convert to ultra-pure water |
| Water parameters: Hardness pH Dissolved oxygen Total Organic carbon Particulate Matter Ammonia Nitrite Metals Pesticides Chlorine Temperature Salinity Intervals of water quality measurement | not reported range: 6.9 to 8.3 range: 3.9 to 9.3 mg/L; mean 6.7 mg/L not reported not reported range: 0 to 27.1 mg/L (unionized 0 - 0.24 mg/L); mean 9.4 mg/L not reported not reported not reported not reported not reported range: 19 to 22.8°C range: 0.6 to 1.2 ppt |
| measurement | temperature monitored daily; pH, conductivity, salinity, DO and ammonia monitored on freshly prepared stock solutions and 72-hr exposure solutions (every 72 hours). |
| Number of replicates/groups: negative control: water treated ones: | 11 replicates for atrazine and negative control; 6 replicates for ethanol, dihydrotestosterone and 17- β estradiol (0.1 μ g/mL) positive controls. |

| Parameter | Details |
|----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Number of organisms per replicate /groups: | 60 - 65 larvae per replicate |
| Biomass loading rate | Initially, 650/L, at Day 7 65/L and at Day 21 onward 16.3/L |
| Test concentrations: nominal: measured: | 0, 1, 10 and 25 μ g/L 1.07 \pm 0.02 μ g/L, 10.3 \pm 0.15 μ g/L, 19.5 \pm 0.21 μ g/L |
| Solvent (type, percentage, if used) | FETAX solution for atrazine treated and negative control steroids and solvent control in 0.0025% ethanol/FETAX. FETAX medium: NaCl 0.625 g/L; NaHCO ₃ 0.096 g/L; KCl 0.03 g/L; CaCl ₂ 0.015 g/L, CaSO ₄ -2H ₂ O 0.06 g/L; MgSO ₄ 0.075 g/L |
| Lighting | 12 hrs light, 12 hrs dark |
| Feeding | not reported |
| Recovery of chemical Level of Quantitation Level of Detection | Measured using ELISA (RAPID Strategic Diagnostics, Newark, DE); approximately 10% of samples verified by second analysis. |
| Positive control {if used, indicate the chemical and concentrations} | dihydrotestosterone (0.1 μ g/L in 0.0025% ethanol) 17- β estradiol (0.1 μ g/L in 0.0025% ethanol) |
| Other parameters, if any | |

2. Observations:

Table 2: Observations

| Criteria | Details |
|-----------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
| Parameters measured including the sublethal effects/toxicity symptoms | water quality (excess food, etc.); % mortality, % showing forelimb emergence, % metamorphosed (complete tail resorption) |

EPA MRID Number 458677-07

| Observation intervals | monitored daily for changes in general health and for parameters described above. | | |
|----------------------------|-----------------------------------------------------------------------------------|--|--|
| Were raw data included? | | | |
| Other observations, if any | | | |

II. <u>RESULTS</u> and <u>DISCUSSION</u>:

Atrazine concentrations in both the freshly prepared stock solutions and the exposure tanks were relatively consistent with nominal values (**Table 3**).

Table 3. Nominal and mean-measured atrazine concentrations in freshly prepared stock solutions and exposure tanks.

| Nominal | Stock Solution | Exposure Tank |
|---------|-------------------------------|---------------------------|
| 1 μg/L | $1.02 \pm 0.03~\mu\text{g/L}$ | $1.07 \pm 0.02~\mu g/L$ |
| 10 μg/L | $9.99 \pm 0.29~\mu g/L$ | $10.3 \pm 0.15~\mu g/L$ |
| 25 μg/L | $21.3 \pm 0.67~\mu\text{g/L}$ | $19.5 \pm 0.21 \ \mu g/L$ |

Estradiol concentrations in exposure tanks A through F ranged from 5,520 pg/mL to 11,700 pg/mL (mean: 9,255 pg/mL) on August 21. On October 5, 2001, estradiol levels ranged from 4,764 to 17,467 pg/mL (mean: 9,897 pg/mL). Therefore, average estradiol concentrations were 0.009 μ g/L and were roughly 9% of the desired nominal estradiol concentration of 0.1%.

Post-hatch mortality across all study groups ranged from 10 to 14% (**Table 4**). There was no difference in post-hatch mortality for atrazine treatments and the negative control (ANOVA, p = 0.2) or for hormone treatments and the ethanol control (ANOVA, p = 0.7). There was no difference in body weight or snout-vent length among atrazine-treated and negative controls. Time to complete metamorphosis (NF stage 66) varied inversely with body weight and SVL; those animals reaching NF-stage 66 first in each tank were significantly larger than those animals that were the last, *i.e.*, animals reaching NF-stage 66 by Day 78, in every treatment (paired t-test, p<0.05). Based on the report figure depicting body weights, the average weight of animals reaching stage 66 first ranged from 0.48 to 0.62 g, while the last animals to reach stage 66 had body weights ranging from 0.26 to 0.30 g. Average snout-vent length for animals reaching stage 66 first ranged from 16 to 17 mm while lengths for animals reaching stage 66 last ranged from 13 to 13.5 mm roughly. Body weight and SVL were also inversely correlated with time to complete metamorphosis in hormone-treated and solvent controls. Body weights for animals reaching stage 66 first in hormone and solvent-treated animals ranged from 0.48 to 0.54 g, while late stage 66 animals ranged from 0.24 to 0.25 g. Estradiol-treated females had significantly longer SVL than solvent controls (ANOVA, p = 0.02).

The percentage of animals reaching complete tail resorption varied between 37 - 52% during the 78-day period. Fewer atrazine-treated (referred to as a "weak trend" by authors) animals reached (ANOVA trend test, p =

EPA MRID Number 458677-07

0.03) and completed tail resorption (ANOVA trend test, p = 0.04). However, the general ANOVA F-test revealed no significant effect of atrazine on either parameter compared to negative controls.

The incidence of gross gonadal deformities was less than 5% in all treatments. The incidence of edema was correlated with atrazine concentration (Cochran-Armitage trend test, Z = -2.3, p = 0.02); however, a chi-square homogeneity test revealed that none of the atrazine concentrations significantly increased the incidence of edema compared to negative controls (p = 0.1). Abnormal swimming was also correlated with atrazine concentration (Cochran-Armitage trend test, Z = -2.90, p = 0.004), but only larvae exposed to 25 μ g atrazine/L exhibited significantly greater incidence of abnormal swimming (chi-square homogeneity test, p = 0.04).

There were no detectable effects on sex ratio with ratios ranging from 48 to 50% males in all treatments except the 25 μg atrazine/L treatment. There was a slight reduction in percentage (45%) of males in the 25 μg atrazine/L. Neither ethanol nor dihyrotestosterone significantly affected sex ratios. Estradiol significantly reduced the percentage of males to 26% and increased the percentage of females to 67%. Approximately 7% of the estradiol-treated animals were classified as intersex based on gross morphology.

Exposure to either 25 μ g atrazine/L or estradiol significantly increased the percentage of individuals with intersex gonads. Although the incidence of intersex increased with increasing atrazine concentrations (Cochran-Armitage, Z= 3.6, p=0.0003), only 25 μ g atrazine/L significantly increased the average incidence of intersex animals (4.7%) per tank compared to negative control (0.6%) (p = 0.0061) (**Table 5**). There was also a significant correlation between the incidence of discontinuous gonads and atrazine concentration (Cochran-Armitage Z=2.9, p=0.0042) although 25 μ g atrazine/L was the only concentration to increase the incidence of discontinuous gonads compared to negative controls. The percentage of intersex gonads was also significantly higher in the estradiol-treated group compared to the solvent control. (Kruskall-Wallis, p=0.01).

Table 5. Total number of frogs identified as intersex by treatment.

| Treatment | Total Animals | Intersex | Percentage |
|------------------|----------------------|----------|------------|
| 0 | 334 | 2 | 0.6% |
| 1 μg atrazine/L | 309 | 3 | 0.97% |
| 10 μg atrazine/L | 276 | 1 | 0.36% |
| 25 μg atrazine/L | 296 | 14 | 4.7% |
| estradiol | 135 | 10 | 7.4% |
| solvent control | 160 | 0 | 0.0% |

Intersex animals in the 25 µg atrazine/L group tended to have obvious testicular or ovarian tissues, while estradiol-treated animals revealed "ambiguous" gonadal tissue in some cases.

There were no significant differences in male dilator muscle size within any of the negative control or atrazine treatments (**Table 6**). Total muscle cross-sectional area was 20 - 25% larger in males than females in all atrazine-treated groups. There were no significant effects of atrazine on total cross-sectional area in females (p = 0.5). Exposure to dihydrotestosterone increased total muscle cross-sectional area approximately 2-fold

EPA MRID Number 458677-07

in both males (p > 0.0001) and females (p < 0.0001). Total muscle cross-sectional area was larger in males than in females in the solvent control group but not in the estradiol and DHT-treated groups.

Table 6. Mean (± standard error) of total dilator muscle cross-sectional area (mm²) in Nieuwkoop Faber stage 66 *Xenopus laevis* exposed to atrazine or sex steroids^a.

| Treatment | Males | Females |
|-----------------------------------|------------------------------|-------------------------------|
| negative FETAX control b | 0.154 ± 0.004 $(n = 45)$ | 0.117 ± 0.006 (n = 11) |
| 1 μg atrazine/L | 0.167 ± 0.005 $(n = 41)$ | 0.118 ± 0.006 (n = 10) |
| 10 μg atrazine/L | 0.168 ± 0.004 $(n = 44)$ | 0.129 ± 0.007 (n = 11) |
| 25 μg atrazine/L | 0.168 ± 0.004 $(n = 42)$ | 0.122 ± 0.006 (n = 12) |
| solvent control (0.0025% ethanol) | 0.161 ± 0.008 (n = 6) | 0.121 ± 0.013 (n = 6) |
| dihydrotestosterone | $0.301 \pm 0.012^* $ (n = 6) | $0.313 \pm 0.024^*$ $(n = 6)$ |
| 17- β estradiol | 0.148 ± 0.010 (n = 6) | 0.141 ± 0.009 (n = 6) |

^a Combined largest cross-sectional area through the right and left laryngeal dilator muscles.

F. REVIEWER'S COMMENTS:

For several days, breeding adults were apparently maintained in ultra-pure water before transitioning them into FETAX.

Although samples were collected at the beginning, middle and end of the study for steroid analyses, the report also states though that estradiol was measured using RIA kit (Diagnostic Products Corporation, Los Angeles, CA; LOD 20 pg/mL). DHT values, though, are reported as nominal, and it is unclear whether any effort was made to measure DHT. Measured estradiol concentrations were $0.009\,\mu\text{g/L}$ and were roughly 9% of nominal. Coefficients of variation for the means ranged from 46.5 to 68.9%.

Water samples were collected of freshly prepared stock solutions and of exposure solutions just prior to renewal.

^b FETAX: frog embryo teratogenesis assay– *Xenopus*.

^{*} significantly grater than ethanol control (p < 0.0001)

EPA MRID Number 458677-07

Although the study starts with 60 to 65 larvae per replicate with 11 replicates in the atrazine-treated groups, the results are expressed in terms of 20 - 30 larvae per replicate. If mortality ranged from 10 to 14%, it would leave roughly 52 larvae per replicate, and 42% of the animals would be unaccounted.. It is assumed that the remaining animals failed to reach metamorphosis by Day 78.

The feeding regime was not discussed; however, the report states that frog brittle feed was analyzed by immunoassay and "yielded inconclusive results". Because immunoassays are specific to the antigen of interest, it is presumed that the immunoassay was for atrazine and that something, presumably atrazine, gave variable results, *i.e.*, "yielded inconclusive results." The report states that since a GC/MS method for analyzing frog brittle has not been developed, no data on the food were available (reported).

Body weights of metamorphs were negatively correlated with the length of time to metamorphosis; the number of intersex animals was positively correlated with atrazine concentration.

Although not discussed in the results section, the number of discontinuous gonads appeared to be positively correlated with atrazine treatment. Extrapolating from the figure depicting the percentage of discontinuous gonads there appeared to be 3.5% in controls, and 4%, 7% and 8% in 1, 10 and 25 μ g atrazine/L. The number of discontinuous gonads was significantly higher than controls in the 25 μ g atrazine/L treatment (chi-square, p < 0.05)

The study concluded that estradiol treatment reduced the number of phenotypic males to 25%; however, previous literature suggested that estradiol treatment should result in 100% females.

Body weights and time to metamorphosis were not reported in the study nor was the feeding regime mentioned. Body weights and lengths were extrapolated from figures.

Although the report concluded that atrazine did not impact length, weight, time to metamorphosis or dilator muscle area relative to controls, it did conclude that exposure to 25 μg atrazine/L appeared to significantly increase the number of intersex males and animals with discontinuous gonads. However, the observation that both body weight and length were inversely correlated with the length of time to complete metamorphosis suggested that animals in all treatment groups were developmentally impaired. In addition, 17- β estradiol treatment only resulted in 67% females, which further suggested that study animals were not entirely responsive to the positive control. Although dissolved oxygen did not appear to drop below 3.9 mg/L, ammonia levels did range as high as 27 mg/L, suggesting that the 50% static renewal and loading rates (number of tadpoles per liter of exposure solution) may have resulted in poor water quality, which in turn, accounted for the slow development of test animals.

Roughly 42% of the animals were assumed not to have reached stage 66 by Day 78, suggesting that a large proportion of the animals were not developing at all. Given the declining condition of the frogs with increased length of time to maturity, it is uncertain whether these animals would have undergone metamorphosis and/or survived. Furthermore, since all the animals in the study had not undergone metamorphosis, the percent initiating metamorphosis, time to metamorphosis and percentage of gonadal abnormalities could not be accurately calculated relative to the total animals used in the study.

After 80 days, only 49-61% of the organisms reached forelimb emergence (stage 58) and only 37-52% completed metamorphosis (stage 66). According to Nieuwkoop and Faber, the nominal days to stages 58 and

EPA MRID Number 458677-07

66 are approximately 44 and 58 days, respectively. Although this can vary between laboratories and conditions, the developmental rates observed in this study are exceedingly slow. (At the National Health and Environmental Effects Research Laboratory researchers typically observe nearly 100% tail resorption in approximately 50-54 days.) Furthermore, there is considerable divergence in development because at least 51-39% of the tested organisms are at or below stage 57, while some have completed metamorphosis.

Taken together, these observations suggest that the organisms were in poor condition. It is unclear, though, how such retarded development could affect sexual differentiation.

The report states that there is no evidence that androgens affected gonadal development in *X. laevis*. While it is apparently true that testosterone is incapable of causing masculinization, DHT, the positive androgen control used in this study, has been shown to masculinize *X. laevis*.

Because only about 50% of the tested organisms reached stage 66, and all of the analyses were conducted on stage 66 organisms, the sampling strategy was probably biased and did not represent the population in the test.

The percentage of tadpoles with abnormal swimming was positively correlated (r=0.41; p=0.006) with atrazine concentration (see attached SAS[©] [Statistical Analysis System, Release 8.01, Cary, North Carolina] output); the percentage of tadpoles with edema was also positively correlated (r= 0.40; p=0.007) with atrazine concentration.

The ability of this study to serve as a sensitive indicator of developmental effects is in question given the seemingly impaired condition of the animals.

G. CONCLUSIONS: Although the report concluded that atrazine did not impact length, weight, time to metamorphosis or dilator muscle area relative to controls, it did conclude that exposure to 25 µg atrazine/L appeared to significantly increase the number of intersex males and animals with discontinuous gonads. However, the observation that both body weight and length were inversely correlated with the length of time to complete metamorphosis suggested that animals in all treatment groups were developmentally impaired. Also, the fact that $17-\beta$ estradiol treatment only resulted in 67% females, further suggested that study animals were not entirely responsive to the positive control. Although dissolved oxygen did not appear to drop below 3.9 mg/L, ammonia levels ranged as high as 27 mg/L suggesting that the 50% static renewal and loading rates (number of tadpoles per liter of exposure solution) may have resulted in poor water quality that could, in turn, impair the development of test animals. Furthermore, roughly 42% of the animals were assumed not to have reached stage 66 by Day 78, suggesting that a large proportion of the animals were not developing at all. Because of the declining condition of the frogs with increased length of time to maturity, it is uncertain whether these animals completed metamorphosis and/or survived. Furthermore, because all the animals in the study had not undergone metamorphosis, the percent initiating metamorphosis, time to metamorphosis and percentage of gonadal abnormalities could not be accurately calculated relative to the total animals used in the study.

This study indicates that only one exposure level (25 ug/L) produced developmental effects in frogs, but because of design problems the study did not establish a dose-response relationship between atrazine exposure and developmental effects in frogs. The ability of this study to serve as a sensitive indicator of developmental effects is also in question because of the impaired condition of the animals.

H. REFERENCES:

Nieuwkoop, P. D. and J. Faber. 1967. Normal table of *Xenopus laevis* (Daudin). North-Holland Publishing Company, Amsterdam.

EPA MRID Number 458677-07

Table 4. Hatching, mortality, metamorphosis, and gross developmental abnormalities in X. laevis tadpoles exposed to atrazine or steroid hormonesa.

| Treatment | Hatching (%) | Mortality ^b (%) | Forelimb Emergence (%) | Tail Resorption (%) | Bent Tails (%) | Edema (%) | Abnormal Swimming (%) |
|---------------------|------------------|----------------------------|---------------------------|---------------------|-----------------|-----------------|-----------------------------|
| Negative | 94.9 ± 1.02 | 10.4 ± 1.07 | 60.8 ± 3.00 | 51.5 ± 2.91 | 0.94 ± 0.43 | 0.15 ± 0.15 | 1.37 ± 0.44 |
| 1 μg/L | 93.6 ± 1.12 | 11.4 ± 1.20 | 59.0 ± 3.31 | 48.4 ± 3.00 | 0.49 ± 0.36 | 0.30 ± 0.30 | 2.15 ± 0.53 |
| $10 \mu g/L$ | 94.5 ± 0.093 | 14.1 ± 0.99 | 52.2 ± 3.85 | 42.3 ± 3.42 | 2.13 ± 0.46 | 0.44 ± 0.23 | 3.12 ± 0.68 |
| 25 μg/L | 96.0 ± 0.82 | 12.4 ± 1.58 | 52.5 ± 2.39 | 44.4 ± 2.14 | 1.22 ± 0.33 | 1.04 ± 0.33 | $3.75 \pm 0.64*$ |
| ethanol (0.0025%) | 93.7 ± 1.47 | 11.7 ± 1.62 | 53.8 ± 4.93 | 46.1 ± 3.84 | 0.84 ± 0.56 | 0.57 ± 0.36 | 1.99 ± 0.73 |
| Dihydrotestosterone | 94.6 ± 2.32 | 12.2 ± 2.84 | 48.8 ± 5.36 | 37.2 ± 4.86 | 0.80 ± 0.36 | 1.38 ± 0.49 | 2.98 ± 0.94 |
| 17-β estradiol | 92.9 ± 2.21 | 15.2 ± 4.16 | 51.2 ± 1.91 | 42.8 ± 2.28 | 0.82 ± 0.37 | 0.57 ± 0.36 | 1.69 ± 0.60 |

^a Values are the mean ± standard error of eleven (FETAX medium) or six (ethanol co-solvent) replicates. Sample size per replicate ranged from 20 - 30 animals.

^b 80-day post-hatch mortality.

^{*} significantly different from FETAX medium (negative) control

| as and Gonadai and Laryngeai Morphology | | | | | EPA MRID Number 458677-07 | | |
|-----------------------------------------|--------------|----------------------|-------------------|---------------------|---------------------------|---------|-----|
| | PERCENT | SURVIVAL B | Y TREATMENT | GROUP | | | 236 |
| Obs | TREAT | _TYPE_ | _FREQ_ | SURVIVE | STD | CV | |
| 1 | 0.0 | 0 | 11 | 89.5720 | 3.5310 | 3.9420 | |
| 2 | 1.0 | 0 | 11 | 88.5690 | 3.9837 | 4.4979 | |
| 3 | 10 | 0 | 11 | 85.9008 | 3.2759 | 3.8136 | |
| 4 | 25 | 0 | 11 | 87.6466 | 5.2333 | 5.9709 | |
| 5 | DHT | 0 | 6 | 87.8023 | 6.9606 | 7.9276 | |
| 6 | | 0 | 6 | | | 4.4884 | |
| 7 | ETOH Estr | 0 | 6 | 88.2824 84.8416 | 3.9624 10.1787 | 11.9972 | |
| , | | | | | | 11.7572 | 025 |
| | | | GGS HATCHED | | | | 237 |
| 0bs | TREAT | _TYPE_ | _FREQ_ | HATCHED | STD | CV | |
| 1 | 0.0 | 0 | 11 | 94.9294 | 3.38528 | 3.56610 | |
| 2 | 1.0 | 0 | 11 | 93.6032 | 3.70056 | 3.95346 | |
| 3 | 10 | 0 | 11 | 94.5459 | 3.09986 | 3.27868 | |
| 4 | 25 | 0 | 11 | 95.9701 | 2.71563 | 2.82966 | |
| 5 | DHT | 0 | 6 | 94.5905 | 5.68238 | 6.00734 | |
| 6 | ETOH | 0 | 6 | 93.6631 | 3.59493 | 3.83815 | |
| 7 | Estr | 0 | 6 | 92.8788 | 5.41676 | 5.83207 | |
| , | | | | | TREATMENT GROU | | 238 |
| Ole - | | | | | | | 230 |
| 0bs | TREAT | _TYPE_ | _FREQ_ | BENT | STD | CV | |
| 1 | 0.0 | 0 | 11 | 0.93716 | 1.41694 | 151.195 | |
| 2 | 1.0 | 0 | 11 | 0.48822 | 1.17785 | 241.256 | |
| 3 | 10 | 0 | 11 | 2.12556 | 1.52127 | 71.571 | |
| 4 | 25 | 0 | 11 | 1.21942 | 1.11046 | 91.064 | |
| 5 | DHT | 0 | 6 | 0.80232 | 0.87911 | 109.570 | |
| 6 | ETOH | 0 | 6 | 0.83525 | 1.37177 | 164.234 | |
| 7 | Estr | 0 | 6 | 0.82068 | 0.90009 | 109.676 | |
| | PERCEI | NT OF TADPO | LES WITH EDI | EMA BY TR | EATMENT GROUP | | 239 |
| 0bs | TREAT | _TYPE_ | _FREQ_ | EDEMA | STD | CV | |
| 1 | 0.0 | 0 | 11 | 0.14903 | 0.49428 | 331.662 | |
| 2 | 1.0 | 0 | 11 | 0.30311 | 0.67450 | 222.524 | |
| 3 | 10 | 0 | 11 | 0.43770 | 0.74986 | 171.316 | |
| 4 | 25 | 0 | 11 | 1.03520 | 1.08659 | 104.965 | |
| | | 0 | 6 | | 1.21355 | 87.992 | |
| 5 | DHT | | | 1.37917 | | | |
| 6 | ETOH | 0 | 6 | 0.56644 | 0.87922 | 155.219 | |
| 7 DFF | Estr | 0 דע פידינטסטעניי | б ти авиормат. | 0.56984 SWIMMING | 0.88284 BY TREATMENT | 154.928 | 240 |
| | | | | | | | 210 |
| 0bs | TREAT | _TYPE_ | _FREQ_ | SWIM | STD | CV | |
| 1 | 0.0 | 0 | 11 | 1.37132 | 1.46806 | 107.055 | |
| 2 | 1.0 | 0 | 11 | 2.15034 | 1.76982 | 82.304 | |
| 3 | 10 | 0 | 11 | 3.11772 | 2.25729 | 72.402 | |
| 4 | 25 | 0 | 11 | 3.75251 | 2.13240 | 56.826 | |
| 5 | DHT | 0 | 6 | 2.98382 | 2.30207 | 77.152 | |
| 6 | ETOH | 0 | 6 | 1.98706 | 1.77746 | 89.452 | |
| 7 | Estr | 0 | 6 | 1.69367 | 1.46398 | 86.438 | |
| | | | MORPHOSIS B | | | | 241 |
| Ola - | | | | | | CV. | 211 |
| 0bs | TREAT | _TYPE_ | _FREQ_ | METAMORP | | CV | |
| 1 | 0.0 | 0 | 11 | 51.5133 | | 18.7146 | |
| 2 | 1.0 | 0 | 11 | 48.3625 | | 20.6188 | |
| 3 | 10 | 0 | 11 | 42.2644 | 11.3256 | 26.7971 | |
| 4 | 25 | 0 | 11 | 44.3954 | 7.1060 | 16.0061 | |
| 5 | DHT | 0 | 6 | 37.1615 | 11.8957 | 32.0109 | |
| 6 | ETOH | 0 | 6 | 46.0801 | 9.4053 | 20.4107 | |
| 7 | Estr | 0 | 6 | 42.7528 | | 13.0622 | |
| | | | | | | | |

Page 15 of 41

EPA MRID Number 458677-07

NONPARAMETRIC COMPARISON OF PERCENT METAMORPHOSIS ACROSS TREATMENTS

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable PMET Classified by Variable TREAT

| | | Sum of | Expected | Std Dev | Mean |
|-----------|-----------|-----------------|-----------------|----------------|-------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| âââââââââ | aaaaaaaaa | aaaaaaaaaaaaaaa | âââââââââââââââ | laaaaaaaaaaaaa | lââââââââââ |
| 0.0 | 11 | 459.00 | 346.50 | 54.267424 | 41.727273 |
| 1.0 | 11 | 423.50 | 346.50 | 54.267424 | 38.500000 |
| 10 | 11 | 298.00 | 346.50 | 54.267424 | 27.090909 |
| 25 | 11 | 312.00 | 346.50 | 54.267424 | 28.363636 |
| DHT | 6 | 114.50 | 189.00 | 41.997885 | 19.083333 |
| ETOH | 6 | 199.00 | 189.00 | 41.997885 | 33.166667 |
| Estr | 6 | 147.00 | 189.00 | 41.997885 | 24.500000 |

Average scores were used for ties. Kruskal-Wallis Test

> Chi-Square 9.9774 DF 6 Pr > Chi-Square 0.1256

| | | Sum of | Expected | Std Dev | Mean |
|----------|-------------|----------------|---------------|----------------|------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | .ââââââââââ | àâââââââââââââ | âââââââââââââ | ââââââââââââââ | ââââââââââ |
| 0.0 | 11 | 8.0 | 5.50 | 1.516305 | 0.727273 |
| 1.0 | 11 | 7.0 | 5.50 | 1.516305 | 0.636364 |
| 10 | 11 | 5.0 | 5.50 | 1.516305 | 0.454545 |
| 25 | 11 | 4.0 | 5.50 | 1.516305 | 0.363636 |
| DHT | 6 | 2.0 | 3.00 | 1.173477 | 0.333333 |
| ETOH | 6 | 3.0 | 3.00 | 1.173477 | 0.500000 |
| Estr | 6 | 2.0 | 3.00 | 1.173477 | 0.333333 |

Average scores were used for ties.

Median One-Way Analysis

Chi-Square 5.2473
DF 6
Pr > Chi-Square 0.5125

EPA MRID Number 458677-07

NONPARAMETRIC COMPARISON OF PERCENT SURVIVAL ACROSS TREATMENTS

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable SUR Classified by Variable TREAT

| | | Sum of | Expected | Std Dev | Mean |
|-----------|-----------|------------------|-----------------|-----------------------------------------|-------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| âââââââââ | âââââââââ | àâââââââââââââââ | iââââââââââââââ | âââââââââââââââââââââââââââââââââââââââ | àââââââââââ |
| 0.0 | 11 | 426.50 | 346.50 | 54.251705 | 38.772727 |
| 1.0 | 11 | 377.00 | 346.50 | 54.251705 | 34.272727 |
| 10 | 11 | 240.50 | 346.50 | 54.251705 | 21.863636 |
| 25 | 11 | 328.50 | 346.50 | 54.251705 | 29.863636 |
| DHT | 6 | 208.00 | 189.00 | 41.985719 | 34.666667 |
| ETOH | 6 | 185.50 | 189.00 | 41.985719 | 30.916667 |
| Estr | 6 | 187.00 | 189.00 | 41.985719 | 31.166667 |

Average scores were used for ties. Kruskal-Wallis Test

Chi-Square 5.4728 DF 6 Pr > Chi-Square 0.4848

Median Scores (Number of Points Above Median) for Variable SUR Classified by Variable TREAT

| | | Sum of | Expected | Std Dev | Mean |
|-----------|-----------|------------------|----------------|----------------|------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| âââââââââ | âââââââââ | ââââââââââââââââ | ââââââââââââââ | ââââââââââââââ | ââââââââââ |
| 0.0 | 11 | 7.750 | 5.50 | 1.479165 | 0.704545 |
| 1.0 | 11 | 6.750 | 5.50 | 1.479165 | 0.613636 |
| 10 | 11 | 2.750 | 5.50 | 1.479165 | 0.250000 |
| 25 | 11 | 4.750 | 5.50 | 1.479165 | 0.431818 |
| DHT | 6 | 4.000 | 3.00 | 1.144735 | 0.666667 |
| ETOH | 6 | 2.000 | 3.00 | 1.144735 | 0.333333 |
| Estr | 6 | 3.000 | 3.00 | 1.144735 | 0.500000 |

Average scores were used for ties.

Median One-Way Analysis

Chi-Square 6.9240 DF 6 Pr > Chi-Square 0.3279

EPA MRID Number 458677-07

248

NONPARAMETRIC COMPARISON OF PERCENT OF TADPOLES WITH ABNORMAL SWIMMING ACROSS TREATMENTS 246

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable SWIM Classified by Variable TREAT

| | | Sum of | Expected | Std Dev | Mean |
|----------|------------|------------------|-----------------------------------------|-----------------|------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | ââââââââââ | ââââââââââââââââ | aââââââââââââââââââââââââââââââââââââââ | iaaaaaaaaaaaaaa | ââââââââââ |
| 0.0 | 11 | 243.50 | 346.50 | 53.920541 | 22.136364 |
| 1.0 | 11 | 321.00 | 346.50 | 53.920541 | 29.181818 |
| 10 | 11 | 390.00 | 346.50 | 53.920541 | 35.454545 |
| 25 | 11 | 462.50 | 346.50 | 53.920541 | 42.045455 |
| DHT | 6 | 221.50 | 189.00 | 41.729430 | 36.916667 |
| ETOH | 6 | 150.50 | 189.00 | 41.729430 | 25.083333 |
| Estr | 6 | 164.00 | 189.00 | 41.729430 | 27.333333 |

Average scores were used for ties.

Kruskal-Wallis Test
Chi-Square 9.1688
DF 6
Pr > Chi-Square 0.1643

| | | Sum of | Expected | Std Dev | Mean |
|----------|-----------|----------------|------------------|----------------|------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | âââââââââ | ââââââââââââââ | ââââââââââââââââ | ââââââââââââââ | ââââââââââ |
| 0.0 | 11 | 4.0 | 5.50 | 1.516305 | 0.363636 |
| 1.0 | 11 | 5.0 | 5.50 | 1.516305 | 0.454545 |
| 10 | 11 | 5.0 | 5.50 | 1.516305 | 0.454545 |
| 25 | 11 | 9.0 | 5.50 | 1.516305 | 0.818182 |
| DHT | 6 | 4.0 | 3.00 | 1.173477 | 0.666667 |
| ETOH | 6 | 1.0 | 3.00 | 1.173477 | 0.166667 |
| Estr | 6 | 3.0 | 3.00 | 1.173477 | 0.500000 |

Average scores were used for ties.

Median One-Way Analysis

Chi-Square 8.6461 DF 6 Pr > Chi-Square 0.1945

NONPARAMETRIC COMPARISON OF PERCENT OF TADPOLES WITH BENT TAILS ACROSS TREATMENTS

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable BENT Classified by Variable TREAT

| | | Sum of | Expected | Std Dev | Mean |
|----------|----------|----------------------------------------|---------------|-----------------------------------------|-----------------------------------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | ââââââââ | aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa | âââââââââââââ | âââââââââââââââââââââââââââââââââââââââ | âââââââââââââââââââââââââââââââââââââââ |
| 0.0 | 11 | 323.50 | 346.50 | 50.384440 | 29.409091 |
| 1.0 | 11 | 254.00 | 346.50 | 50.384440 | 23.090909 |
| 10 | 11 | 491.50 | 346.50 | 50.384440 | 44.681818 |
| 25 | 11 | 374.00 | 346.50 | 50.384440 | 34.000000 |
| DHT | 6 | 161.00 | 189.00 | 38.992820 | 26.833333 |
| ETOH | 6 | 174.00 | 189.00 | 38.992820 | 29.000000 |
| Estr | 6 | 175.00 | 189.00 | 38.992820 | 29.166667 |
| | | Average scores | were used fo | r ties. | |

Kruskal-Wallis Test

Chi-Square 10.7175 DF 6

EPA MRID Number 458677-07

Pr > Chi-Square

0.0975

| | | Sum of | Expected | Std Dev | Mean |
|-----------|----------|-------------------|---------------------|----------------|------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| âââââââââ | ââââââââ | âââââââââââââââââ | aaaaaaaaaaaaaaaaaaa | ââââââââââââââ | ââââââââââ |
| 0.0 | 11 | 4.218750 | 5.50 | 1.468156 | 0.383523 |
| 1.0 | 11 | 2.281250 | 5.50 | 1.468156 | 0.207386 |
| 10 | 11 | 9.062500 | 5.50 | 1.468156 | 0.823864 |
| 25 | 11 | 7.125000 | 5.50 | 1.468156 | 0.647727 |
| DHT | 6 | 3.093750 | 3.00 | 1.136215 | 0.515625 |
| ETOH | 6 | 2.125000 | 3.00 | 1.136215 | 0.354167 |
| Estr | 6 | 3.093750 | 3.00 | 1.136215 | 0.515625 |

Average scores were used for ties.

Median One-Way Analysis

Chi-Square 10.9792 DF 6 Pr > Chi-Square 0.0890

NONPARAMETRIC COMPARISON OF PERCENT OF TADPOLES WITH EDEMA ACROSS TREATMENTS

250

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable EDEMA Classified by Variable TREAT

| | | Sum of | Expected | Std Dev | Mean |
|----------|----------|------------------|----------------|---------------|---------------------------------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | ââââââââ | ââââââââââââââââ | ââââââââââââââ | aaaaaaaaaaaaa | a a a a a a a a a a a a a a a a a a a |
| 0.0 | 11 | 266.50 | 346.50 | 45.035250 | 24.227273 |
| 1.0 | 11 | 300.00 | 346.50 | 45.035250 | 27.272727 |
| 10 | 11 | 314.50 | 346.50 | 45.035250 | 28.590909 |
| 25 | 11 | 417.00 | 346.50 | 45.035250 | 37.909091 |
| DHT | 6 | 264.50 | 189.00 | 34.853050 | 44.083333 |
| ETOH | 6 | 192.50 | 189.00 | 34.853050 | 32.083333 |
| Estr | 6 | 198.00 | 189.00 | 34.853050 | 33.000000 |
| | | Average scores | were used fo | or ties. | |

Kruskal-Wallis Test

Chi-Square 10.2116
DF 6
Pr > Chi-Square 0.1160


Median Scores (Number of Points Above Median) for Variable EDEMA Classified by Variable TREAT

| | | Sum of | Expected | Std Dev | Mean |
|----------|-----------|-----------------|---------------------------------------|-----------------|------------|
| TREAT | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | âââââââââ | âââââââââââââââ | a a a a a a a a a a a a a a a a a a a | àââââââââââââââ | ââââââââââ |
| 0.0 | 11 | 3.619048 | 5.50 | 1.046350 | 0.329004 |
| 1.0 | 11 | 4.357143 | 5.50 | 1.046350 | 0.396104 |
| 10 | 11 | 5.095238 | 5.50 | 1.046350 | 0.463203 |
| 25 | 11 | 7.309524 | 5.50 | 1.046350 | 0.664502 |
| DHT | 6 | 4.523810 | 3.00 | 0.809776 | 0.753968 |
| ETOH | 6 | 3.047619 | 3.00 | 0.809776 | 0.507937 |
| Estr | 6 | 3.047619 | 3.00 | 0.809776 | 0.507937 |

Average scores were used for ties.

Median One-Way Analysis

Chi-Square 9.4273
DF 6
Pr > Chi-Square 0.1509



EPA MRID Number 458677-07

CORRELATION ANALYSIS OF PERCENT METAMORPHOSIS OVER CONCENTRATION

53

The CORR Procedure

1 With Variables: CONC 1 Variables: PMET

Simple Statistics


| Variable | N | Mean | Std Dev | Sum | Minimum | Maximum |
|----------|----|----------|----------|-----------|----------|----------|
| CONC | 44 | 9.00000 | 10.14087 | 396.00000 | 0 | 25.00000 |
| PMET | 44 | 46.63390 | 9.96659 | 2052 | 19.67213 | 66.66667 |

Pearson Correlation Coefficients, N = 44 Prob > |r| under H0: Rho=0

PMET

CONC -0.24787 0.1047

EPA MRID Number 458677-07




Pearson Correlation Coefficients, N = 44 Prob > |r| under H0: Rho=0

SWIM

CONC 0.40804 0.0060

EPA MRID Number 458677-07




Pearson Correlation Coefficients, N = 44 Prob > |r| under H0: Rho=0


EDEMA

CONC 0.40388 0.0066

EPA MRID Number 458677-07

| | Mean | Body Weigl | ht of Frog | s by Treatm | ent | 1202 |
|-----|-------|------------|------------|-------------|------------|------|
| 0bs | treat | _TYPE_ | _FREQ_ | MEAN | STDERR | |
| 1 | 0.0 | 0 | 335 | 0.32519 | .005212036 | |
| 2 | 1.0 | 0 | 312 | 0.31670 | .005086144 | |
| 3 | 10 | 0 | 277 | 0.34574 | .006660663 | |
| 4 | 25 | 0 | 299 | 0.32173 | .005397997 | |
| 5 | DHT | 0 | 135 | 0.32539 | .008838205 | |
| 6 | ETOH | 0 | 161 | 0.31324 | .007248717 | |
| 7 | Estr | 0 | 151 | 0.32720 | .007594965 | |





EPA MRID Number 458677-07

Analysis of Variance for Frog Body Weight over Treatment

1204

The GLM Procedure

Class Level Information

Class Levels Values

6

treat 7 0.0 1.0 10 25 DHT ETOH Estr

Number of observations 1670

NOTE: Due to missing values, only 1661 observations can be used in this analysis.

Dependent Variable: BW

treat

| Source | | DF | Sum Squa | | Mean So | quare | F Value | Pr > F |
|-----------------|----------------------|------|------------------|---------------|---------|-------|---------|--------|
| Model | | 6 | 0.16575 | 046 | 0.0276 | 52508 | 2.96 | 0.0071 |
| Error | | 1654 | 15.45132 | 260 | 0.0093 | 34179 | | |
| Corrected Total | | 1660 | 15.61707 | 306 | | | | |
| | R-Square 0.010613 | | ff Var .69766 | Root 0.096 | | BW Me | | |
| | | | | | | | | |
| Source | | DF | Type I | SS | Mean So | quare | F Value | Pr > F |
| treat | | 6 | 0.16575 | 046 | 0.0276 | 2508 | 2.96 | 0.0071 |
| Source | | DF | Type III | SS | Mean So | quare | F Value | Pr > F |

0.16575046

0.02762508

2.96

0.0071

EPA MRID Number 458677-07

Analysis of Variance for Frog Body Weight over Treatment

1206

1207

The GLM Procedure

Levene's Test for Homogeneity of BW Variance ANOVA of Squared Deviations from Group Means

| Source | DF | Sum of Squares | Mean Square | F Value | Pr > F |
|----------------|-----------|-------------------|----------------|---------|--------|
| treat Error | 6 1654 | 0.00343 | 0.000571 | 1.40 | 0.2098 |

Bartlett's Test for Homogeneity of BW Variance

Source DF Chi-Square Pr > ChiSq

treat 6 17.8554 0.0066
Analysis of Variance for Frog Body Weight over Treatment

The GLM Procedure

Dunnett's t Tests for BW

NOTE: This test controls the Type I experimentwise error for comparisons of all treatments against a control.

Alpha 0.05
Error Degrees of Freedom 1654
Error Mean Square 0.009342
Critical Value of Dunnett's t 2.59779

Comparisons significant at the 0.05 level are indicated by ***.

| | Difference | | | |
|------------|------------|-----------|----------|-----|
| treat | Between | Simultan | eous 95% | |
| Comparison | Means | Confidenc | e Limits | |
| | | | | |
| 10 - 0.0 | 0.020549 | 0.000124 | 0.040974 | *** |
| Estr - 0.0 | 0.002005 | -0.022617 | 0.026628 | |
| DHT - 0.0 | 0.000197 | -0.025410 | 0.025804 | |
| 25 - 0.0 | -0.003465 | -0.023509 | 0.016578 | |
| 1.0 - 0.0 | -0.008491 | -0.028309 | 0.011328 | |
| ETOH = 0.0 | -0 011958 | -0.036098 | 0 012183 | |

EPA MRID Number 458677-07

Nonparametric comparison of frog body weight over treatments

1208

1210

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable BW Classified by Variable treat

| | | Sum of | Expected | Std Dev | Mean |
|----------|----------|------------------|-------------|-----------------|-------------|
| treat | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | aâââââââ | ââââââââââââââââ | âââââââââââ | àââââââââââââââ | âââââââââââ |
| 0.0 | 334 | 279296.50 | 277554.0 | 7834.89949 | 836.217066 |
| 1.0 | 309 | 244939.50 | 256779.0 | 7606.63049 | 792.684466 |
| 10 | 276 | 254956.50 | 229356.0 | 7276.19220 | 923.755435 |
| 25 | 296 | 242002.00 | 245976.0 | 7480.60832 | 817.574324 |
| DHT | 135 | 109378.50 | 112185.0 | 5341.56953 | 810.211111 |
| ETOH | 160 | 122301.50 | 132960.0 | 5767.33359 | 764.384375 |
| Estr | 151 | 127416.50 | 125481.0 | 5619.55184 | 843.817881 |
| | | Average scores | were used | for ties. | |

Kruskal-Wallis Test

Chi-Square 16.0133
DF 6
Pr > Chi-Square 0.0137

 $\begin{tabular}{lll} Median Scores (Number of Points Above Median) for Variable BW \\ Classified by Variable treat \\ \end{tabular}$

| | | Sum of | Expected | Std Dev | Mean |
|----------|----------|-----------------|-----------------|----------------------|------------|
| treat | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | ââââââââ | .ââââââââââââââ | laaaaaaaaaaaaaa | aaaaaaaaaaaaaaaaaaaa | ââââââââââ |
| 0.0 | 334 | 178.0 | 166.899458 | 8.170047 | 0.532934 |
| 1.0 | 309 | 143.0 | 154.406984 | 7.932014 | 0.462783 |
| 10 | 276 | 162.0 | 137.916918 | 7.587441 | 0.586957 |
| 25 | 296 | 141.0 | 147.910897 | 7.800601 | 0.476351 |
| DHT | 135 | 61.0 | 67.459362 | 5.570062 | 0.451852 |
| ETOH | 160 | 67.0 | 79.951836 | 6.014039 | 0.418750 |
| Estr | 151 | 78.0 | 75.454545 | 5.859935 | 0.516556 |


Average scores were used for ties.


Median One-Way Analysis

Chi-Square 17.8022 DF 6 Pr > Chi-Square 0.0067

Average Snout to Vent Length of Frogs by Treatment

| Obs | treat | _TYPE_ | _FREQ_ | MEAN | STDERR |
|-----|-------|--------|--------|---------|---------|
| 1 | 0.0 | 0 | 335 | 13.9566 | 0.08149 |
| 2 | 1.0 | 0 | 312 | 13.7896 | 0.07939 |
| 3 | 10 | 0 | 277 | 14.0815 | 0.09106 |
| 4 | 25 | 0 | 299 | 13.9865 | 0.09052 |
| 5 | DHT | 0 | 135 | 13.9963 | 0.13501 |
| 6 | ETOH | 0 | 161 | 13.5938 | 0.10530 |
| 7 | Estr | 0 | 151 | 14.2914 | 0.11416 |





EPA MRID Number 458677-07

Analysis of Variance for Frog Snout to Vent Length over Treatment

1212

The GLM Procedure

Class Level Information Class Values Levels

0.0 1.0 10 25 DHT ETOH Estr treat

> Number of observations 1670

NOTE: Due to missing values, only 1661 observations can be used in this analysis.

Dependent Variable: SVL

treat

| | | Sum of | | | |
|-----------------|------|-------------|-------------|---------|--------|
| Source | DF | Squares | Mean Square | F Value | Pr > F |
| Model | 6 | 51.322535 | 8.553756 | 3.94 | 0.0006 |
| Error | 1654 | 3590.329783 | 2.170695 | | |
| Corrected Total | 1660 | 3641 652318 | | | |

| | R-Square | Coe | eff Var | Root | MSE | SVL Mean | | |
|-----------------|----------|---------|-----------------------|-------|---------------------|----------|---------------|------------------|
| | 0.014093 | 10 | .56124 | 1.473 | 328 | 13.95033 | | |
| Source treat | | DF 6 | Type I 51.32253 | | Mean Squ 8.55375 | | Value 3.94 | Pr > F 0.0006 |
| Source treat | | DF 6 | Type III 51.322535 | | Mean Squ 8.55375 | | Value 3.94 | Pr > F 0.0006 |

Levene's Test for Homogeneity of SVL Variance ANOVA of Squared Deviations from Group Means

| Source | DF | Sum of Squares | Mean Square | F Value | Pr > F |
|----------------|-----------|--------------------|--------------------|---------|--------|
| treat Error | 6 1654 | 81.5820 20484 3 | 13.5970 12.3847 | 1.10 | 0.3612 |

Bartlett's Test for Homogeneity of SVL Variance

Source DF Chi-Square Pr > ChiSq treat 8.9126 0.1786

Dunnett's t Tests for SVL

NOTE: This test controls the Type I experimentwise error for comparisons of all treatments against a control.

> Alpha 0.05 Error Degrees of Freedom 1654 Error Mean Square 2.170695 Critical Value of Dunnett's t 2.59779

Comparisons significant at the 0.05 level are indicated by ***.

| treat Comparison | Difference Between Means | Simultaneous 95% Confidence Limits |
|---------------------|--------------------------------|------------------------------------------|
| Estr - 0.0 | 0.3348 | -0.0405 0.7101 |
| 10 - 0.0 | 0.1249 | -0.1864 0.4363 |
| DHT - 0.0 | 0.0397 | -0.3506 0.4301 |
| 25 - 0.0 | 0.0299 | -0.2756 0.3354 |
| 1.0 - 0.0 | -0.1669 | -0.4690 0.1352 |
| ETOH - 0.0 | -0.3628 | -0.7308 0.0052 |

EPA MRID Number 458677-07

Nonparametric comparison of frog length over treatments

1216

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable SVL Classified by Variable treat

| | | Sum of | Expected | Std Dev | Mean |
|----------|-----------|------------------|-------------|-----------------------------------------|--------------|
| treat | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | âââââââââ | ââââââââââââââââ | âââââââââââ | aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa | aâââââââââââ |
| 0.0 | 334 | 277451.50 | 277554.0 | 7761.12060 | 830.693114 |
| 1.0 | 309 | 243946.50 | 256779.0 | 7535.00115 | 789.470874 |
| 10 | 276 | 241172.50 | 229356.0 | 7207.67449 | 873.813406 |
| 25 | 296 | 247542.00 | 245976.0 | 7410.16568 | 836.290541 |
| DHT | 135 | 113146.50 | 112185.0 | 5291.26958 | 838.122222 |
| ETOH | 160 | 114795.50 | 132960.0 | 5713.02434 | 717.471875 |
| Estr | 151 | 142236.50 | 125481.0 | 5566.63421 | 941.963576 |
| | | Average scores | were used | for ties. | |

Kruskal-Wallis Test

Chi-Square 22.0409
DF 6
Pr > Chi-Square 0.0012

| | | Sum of | Expected | Std Dev | Mean |
|----------|-----------|----------------|------------------|-----------------|------------|
| treat | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | âââââââââ | ââââââââââââââ | ââââââââââââââââ | âââââââââââââââ | ââââââââââ |
| 0.0 | 334 | 166.322485 | 166.899458 | 7.423923 | 0.497972 |
| 1.0 | 309 | 141.224852 | 154.406984 | 7.207627 | 0.457038 |
| 10 | 276 | 150.535503 | 137.916918 | 6.894522 | 0.545418 |
| 25 | 296 | 150.807692 | 147.910897 | 7.088216 | 0.509485 |
| DHT | 135 | 68.059172 | 67.459362 | 5.061379 | 0.504142 |
| ETOH | 160 | 65.059172 | 79.951836 | 5.464810 | 0.406620 |
| Estr | 151 | 87.991124 | 75.454545 | 5.324780 | 0.582723 |

Average scores were used for ties.

Median One-Way Analysis


Chi-Square 17.4213
DF 6
Pr > Chi-Square 0.0079

| Metamorphosis and | | | | <i>-,</i> | EPA MRID Nun | aber 458677-07 |
|-------------------|-------------------------------|----------------------------|------------------------------|---------------------------------------------------------------|------------------------------------------|----------------|
| - | | Percenta | ge of Frogs | Male or Femal | | 1218 |
| | | | treat=0 | .0 | | |
| | | | The FREQ Pr | ocedure | | |
| | Sex âââââââ | Frequency âââââââââââââ | .âââââââââââ | Cumulative Frequency ââââââââââââââ | Percent ââââââââââââ | |
| | ? F M | 2 168 164 | 0.60 50.30 49.10 | 2 170 334 | 0.60 50.90 100.00 | |
| | | | equency Mis ge of Frogs | sing = 1 Male or Femal | e | 1219 |
| | | | treat=1 | .0 | | |
| | | | The FREQ Pr | ocedure | | |
| | | aaaaaaaaaaaa 3 152 | âââââââââââ 0.97 49.19 | Cumulative Frequency âââââââââââââ 3 155 309 | Percent ââââââââââââ 0.97 50.16 | |
| | | | equency Mis | sing = 3 Male or Femal | ٩ | 1220 |
| | | | 5 | | | |
| | | | | | | |
| | | | The FREQ Pr | | | |
| | Sex âââââââ ? F M | âââââââââââââââ | âââââââââââ 0.36 51.45 | Cumulative Frequency âââââââââââââââ 1 143 276 | Percent ââââââââââââ 0.36 51.81 | |

Frequency Missing = 1

| Metamorphosis and | | | | . 0, | | EPA MRID N | umber 458677-07 |
|-------------------|------------|-----------------------------------------|-----------------------------------------|----------------|-------------------------|----------------------------------|-----------------|
| | | Pero | centage of | Frogs Ma | ale or Femal | | 1221 |
| | | | t | reat=25 | | | |
| | | | The FR | EQ Proce | edure | | |
| | | | 1110 111 | | | | |
| | Sex | Frequenc | cy Perc | | Cumulative Frequency | Cumulative Percent | |
| | âââââ | aaaaaaāaaaa | aāaaaaaaaaa | ââââââââ | àaaaaaaaaaaa | ââââââââââ | |
| | ? F | 149 149 | | | 14 163 | 4.73 55.07 | |
| | r M | 133 | | | 296 | | |
| | | | _ | | 2 | | |
| | | Pero | Frequenc | | ng = 3 ale or Femal | e | 1222 |
| | | | | | | | |
| | | | tr | eat=DHT | | | |
| | | | The FR | EQ Proce | edure | | |
| | | | | | Tumulative | Cumulative | |
| | Sex | Frequenc | cy Perc | | Frequency | | |
| | | a â â â â â â â â â â â â â â â â â â â | âââââââââââââââââââââââââââââââââââââââ | ââââââââ | àâââââââââââ | ââââââââââ | |
| | F M | 7: | 3 54. | 07 | 73 135 | 54.07 100.00 | |
| | 1-1 | | | | ale or Femal | | 1223 |
| | | | | EEOT | • | | |
| | | | tr | eat=ETOE | 1 | | |
| | | | The FR | EQ Proce | edure | | |
| | | | | C | Cumulative | Cumulative | |
| | | | | | Frequency | | |
| | aaaaa F | | aaaaaaaaaa 1 50. | aaaaaaaa 63 | aaaaaaaaaa 81 | ââââââââââ 50.63 | |
| | M | | 9 49. | 38 | 160 | 100.00 | |
| | | | F | Mi | 1 | | |
| | | Pero | Frequenc centage of | | ng = 1 ale or Femal | e | 1224 |
| | | | _ | - | | | |
| | | | tr | eat=Estr | ? | | |
| | | | The FR | EQ Proce | edure | | |
| | | | | | lumulative | Cumulative | |
| | Sex | | | | | Cumulative Percent | |
| | | | | | | âââââââââââ | |
| | ? F | 10 10 | | | 11 112 | 7.28 74.17 | |
| | M | 39 | | | 151 | 100.00 | |
| | | Average To | otal Area o | f Frog I | Larynx by Tr | eatment | 1225 |
| | 0bs | treat | _TYPE_ | _FREQ_ | MEAN | STDERR | |
| | 1 | 0.0 | 0 | 56 | 0.14694 | 0.003893 | |
| | 2 | 1.0 | 0 | 51 | 0.15720 | 0.005215 0.003926 0.004347 | |
| | 3 | 10 | 0 | 55 | 0.15998 | 0.003926 | |
| | 4 5 | 25 | 0 | 54 | 0.15752 | 0.004347 | |
| | 5 6 | DHT ETOH | 0 | 12 12 | 0.30669 0.14100 | 0.012958 0.009301 | |
| | 7 | Estr | 0 | 12 | 0.14480 | 0.006760 | |
| | , | TO CT | U | 14 | 0.14400 | 0.000/00 | |

EPA MRID Number 458677-07



| | | | | | | E | PA MRID N | lumber 4580 | 677-07 |
|---------------------------------------|----------------|---------------------------|----------------------|-------------------------------------------|-----------------------------|-------------|------------------|------------------|--------|
| | Analysis | of Variand | e for Lar | ynx Tota | l Area ov | ver Tre | eatment | | 1227 |
| | | | The GLM | Procedur | e | | | | |
| | | C] | ass Level | Informa | tion | | | | |
| | Class treat | Le | | alues .0 1.0 1 | 0 25 DHT | ETOH E | Sstr | | |
| | | Numbe | er of obse | rvations | 252 | | | | |
| Dependent Varial | ole: TOTAL | | | | | | | | |
| Source Model Error Corrected | Total | DF 6 245 251 | Sq 0.275 | um of uares 15908 49096 65004 | Mean So 0.0458 0.0010 | 35985 | F Value 43.98 | Pr > F <.0001 | |
| | R-Sq | uare Co | eff Var | Root | MSE T | COTAL M | lean | | |
| | 0.51 | 8532 2 | 20.01396 | 0.03 | 2293 | 0.161 | .351 | | |
| Source treat | | DF 6 | | I SS 15908 | Mean Sc 0.0458 | | F Value 43.98 | Pr > F < .0001 | |
| Source treat | | DF 6 | Type I 0.275 | II SS 15908 | Mean So 0.0458 | | F Value 43.98 | Pr > F <.0001 | |
| | | ene's Test OVA of Squa | | | | | ce | | |
| | Source | DF | Sum of Squares | Me Squa | an re F V | /alue | Pr > F | | |
| | treat Error | | 0.000021 | 3.543E 1.945E | | 1.82 | 0.0955 | | |
| | Bar | tlett's Tes | st for Hom | ogeneity | of TOTAL | . Varia | ance | | |
| | S | ource | DF C | hi-Squar | e Pr | · ChiSq | I | | |
| | t: | reat | 6 | 9.116 | 1 | 0.1672 | 2 | | |
| | | Dunr | nett's t T | ests for | TOTAL | | | | |
| NOTE: This te | st controls | the Type I | experimen against | | | compari | sons of all | treatment | S |
| | | Alpha Error Dec | grees of F | reedom | (| 0.05 245 | | | |

Alpha 0.05
Error Degrees of Freedom 245
Error Mean Square 0.001043
Critical Value of Dunnett's t 2.62465

Comparisons significant at the 0.05 level are indicated by ***.

| treat | Between | Simultan | eous 95% | |
|------------|-----------|-----------|----------|-----|
| Comparison | Means | Confidenc | e Limits | |
| DHT - 0.0 | 0.159753 | 0.132791 | 0.186715 | *** |
| 10 - 0.0 | 0.013036 | -0.003054 | 0.029126 | |
| 25 - 0.0 | 0.010574 | -0.005591 | 0.026739 | |
| 1.0 - 0.0 | 0.010257 | -0.006148 | 0.026663 | |
| Estr - 0.0 | -0.002144 | -0.029106 | 0.024817 | |
| ETOH - 0.0 | -0.005940 | -0.032901 | 0.021022 | |

EPA MRID Number 458677-07

Nonparametric comparison of frog total larynx area over treatments

1231

The NPAR1WAY Procedure

Wilcoxon Scores (Rank Sums) for Variable TOTAL Classified by Variable treat

| | | Sum of | Expected | Std Dev | Mean |
|----------|-----------|------------------|-----------------------------------------|----------------|-------------|
| treat | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | aââââââââ | ââââââââââââââââ | à â â â â â â â â â â â â â â â â â â â | ââââââââââââââ | âââââââââââ |
| 0.0 | 56 | 5953.0 | 7084.00 | 481.051626 | 106.303571 |
| 1.0 | 51 | 6269.0 | 6451.50 | 464.892730 | 122.921569 |
| 10 | 55 | 7427.0 | 6957.50 | 477.951793 | 135.036364 |
| 25 | 54 | 6899.0 | 6831.00 | 474.787321 | 127.759259 |
| DHT | 12 | 2956.0 | 1518.00 | 246.414285 | 246.333333 |
| ETOH | 12 | 1161.0 | 1518.00 | 246.414285 | 96.750000 |
| Estr | 12 | 1213.0 | 1518.00 | 246.414285 | 101.083333 |

Kruskal-Wallis Test

Chi-Square 41.0845
DF 6
Pr > Chi-Square <.0001

 $\begin{array}{c} {\tt Median \ Scores \ (Number \ of \ Points \ Above \ Median) \ for \ Variable \ TOTAL} \\ {\tt Classified \ by \ Variable \ treat} \end{array}$

| | | Sum of | Expected | Std Dev | Mean |
|----------|-----------|-----------------|---------------|------------------|------------|
| treat | N | Scores | Under H0 | Under H0 | Score |
| ââââââââ | aââââââââ | âââââââââââââââ | âââââââââââââ | ââââââââââââââââ | ââââââââââ |
| 0.0 | 56 | 23.0 | 28.00 | 3.306398 | 0.410714 |
| 1.0 | 51 | 24.0 | 25.50 | 3.195334 | 0.470588 |
| 10 | 55 | 32.0 | 27.50 | 3.285092 | 0.581818 |
| 25 | 54 | 25.0 | 27.00 | 3.263342 | 0.462963 |
| DHT | 12 | 12.0 | 6.00 | 1.693672 | 1.000000 |
| ETOH | 12 | 5.0 | 6.00 | 1.693672 | 0.416667 |
| Estr | 12 | 5.0 | 6.00 | 1.693672 | 0.416667 |

Median One-Way Analysis

| Chi-Square | 16.3328 |
|-----------------|---------|
| DF | 6 |
| Pr > Chi-Square | 0.0121 |

EPA MRID Number 458677-07

| | | | | | EPA MRID N | umber 458677-07 |
|---------------------------------------------|--------------|------------|-------------------------------------------------------------|-----------------------------------------|----------------------|-----------------|
| Analys | sis of Varia | nce for La | rynx Total | Area over Trea | atment by Sex | 1233 |
| | | | Sex=F | | | |
| | | The | GLM Procedu | re | | |
| | | Class I | Level Inform | ation | | |
| | Class | Levels | Values | | | |
| | treat | 7 | 0.0 1.0 | 10 25 DHT ETOR | H Estr | |
| | | | | | | |
| Dependent Variable: TO | TAL | Number of | observation | ns 62 | | |
| Source Model Error Corrected Total | | 55 0 | Sum of Squares 0.19693080 0.04194645 0.23887726 | Mean Square 0.03282180 0.00076266 | e F Value 0 43.04 | Pr > F < .0001 |
| | R-Square | Coeff V | /ar Roo | t MSE TOTAI | L Mean | |
| | 0.824402 | 19.465 | 572 0.0 | 27616 0.1 | 141872 | |
| Source treat | | | Type I SS).19693080 | 0.03282180 | | <.0001 |
| Source treat | | | pe III SS 0.19693080 | Mean Square 0.03282180 | F Value 43.04 | Pr > F <.0001 |
| | | | | of TOTAL Varia | | |
| Source | ce DF | | | ean are F Value | e Pr > F | |
| treat Erro | | | 034 5.612 055 9.985 | | 2 0.0001 | |
| | Bartlett' | s Test for | . Homogeneit | y of TOTAL Var | riance | |
| | Source | DF | Chi-Squa | re Pr > Chi | iSq | |
| | treat | 6 | 16.32 | 29 0.01 | 121 | |
| | | Dunnett's | s t Tests fo | r TOTAL | | |
| NOTE: This test cont | crols the Ty | | rimentwise e inst a contr | | arisons of all | treatments |
| | | r Degrees | of Freedom | 0.05 55 0.000763 | | |

Error Mean Square 0.000763 Critical Value of Dunnett's t 2.67093

Comparisons significant at the 0.05 level are indicated by ***.

| treat Comparison | Difference Between Means | Simultan Confidence | | |
|---------------------|--------------------------------|------------------------|---------|-----|
| DHT - 0.0 | 0.19547 | 0.15804 | 0.23291 | *** |
| Estr - 0.0 | 0.02421 | -0.01322 | 0.06165 | |
| 10 - 0.0 | 0.01164 | -0.01981 | 0.04310 | |
| 25 - 0.0 | 0.00455 | -0.02624 | 0.03534 | |
| ETOH - 0.0 | 0.00380 | -0.03364 | 0.04123 | |
| 1.0 - 0.0 | 0.00047 | -0.03176 | 0.03269 | |

EPA MRID Number 458677-07

| Analys | sis of Varia | ance for | Larynx | Total Ar | ea ove | | | 123 | |
|---------------------------------------------|-----------------------------|----------------------------------|-------------------------------|------------------------------------------|---------------|-------------------------------|------------------|----------------|---|
| | | | Se | x=M | | | | | _ |
| | | Tì | ne GLM | Procedure | 2 | | | | |
| | | Q] a q | - Torrol | Informat | don | | | | |
| | | | | | TOU | | | | |
| | Class | Leve | ls V | alues | | | | | |
| | treat | | 7 0 | .0 1.0 10 |) 25 DH | T ETOH Es | str | | |
| | | Number o | of obse | rvations | 190 | | | | |
| Dependent Variable: TO | OTAL | | | | | | | | |
| Source Model Error Corrected Total | | DF 6 183 189 | Sq | | 0.01 | Square 948560 078501 | F Value 24.82 | | |
| | R-Square | Coef | f Var | Root | MSE | TOTAL Me | ean | | |
| | 0.448683 | 16. | 70652 | 0.028 | 3018 | 0.167 | 707 | | |
| Source treat | | DF 6 | Type 0.116 | I SS 91360 | Mean 0.01 | Square 948560 | F Value 24.82 | Pr > F < .0001 | |
| Source treat | Levene's ANOVA o | DF 6 Test for f Squared | r Homog | II SS 91360 eneity of tions fro | 0.01 TOTAL | 948560 Variance | F Value 24.82 | Pr > F < .0001 | |
| 9 | | | um of | | | 77.7 | D | | |
| Sourc | | | uares | _ | | Value | | | |
| treat Erron | | 6 9.28 3 0.00 | 84E-6 00235 | 1.547E- 1.286E- | | 1.20 | 0.3067 | | |
| | Bartlett | 's Test | for Hom | ogeneity | of TOT | AL Varian | nce | | |
| | Source | | | hi-Square | | | | | |
| | treat | | 6 | _ | | 0.3748 | | | |
| | 01000 | Dunnet | | ests for | | 0.0710 | | | |
| NOTE: This test cont | crols the T | ype I exj | perimen | | or for | comparis | sons of all | treatments | |
| | Alpi Erro Erro Cri | or Degree or Mean S | es of F Square lue of : | reedom Dunnett's | 0.0 s t 2. | 0.05 183 00785 63648 | | | |

Comparisons significant at the 0.05 level are indicated by ***.

| treat Comparison | Difference Between Means | Simultan Confidenc | eous 95% e Limits | |
|---------------------|--------------------------------|-----------------------|----------------------|-----|
| DHT - 0.0 | 0.146489 | 0.114385 | 0.178594 | *** |
| 10 - 0.0 | 0.013549 | -0.002112 | 0.029210 | |
| 25 - 0.0 | 0.013522 | -0.002327 | 0.029371 | |
| 1.0 - 0.0 | 0.012629 | -0.003319 | 0.028578 | |
| ETOH - 0.0 | 0.006778 | -0.025327 | 0.038882 | |

Page 41 of 41